Summit Therapeutics appoints Dr. Urte Gayko to Board of Directors

Summit Therapeutics Inc.

Dr. Urte Gayko appointed to Summit's Board effective Nov 3, 2021; will serve on Nominating and Corporate Governance Committee.
Gayko is SVP of Drug Development & Regulatory Affairs at Nektar Therapeutics; previously Global Head of Regulatory at Pharmacyclics.
Over 20 years experience in regulatory and clinical development across Amgen, AbbVie, and biotech; PhD in molecular/cellular biology from Harvard.
She received an option grant under Summit's non-employee director compensation policy; also standard indemnification agreement.
Board determined Gayko qualifies as independent director under Nasdaq listing rules.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Urte Gayko

director

SMMT · Summit Therapeutics Inc.

Effective: 2021-11-03
Filed: November 3, 2021, 7:59 PM ET

Effective on November 3, 2021, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved (i) the election of Urte Gayko as a director of the Company, to occupy a newly created seat on the Board and (ii) the appointment of Dr. Gayko to serve on the Nominating and Corporate Governance Committee.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Urte Gayko was elected as director at Summit Therapeutics Inc..

Action: elected
Role: director

Exact text from the filing

Effective on November 3, 2021, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved (i) the election of Urte Gayko as a director of the Company, to occupy a newly created seat on the Board and (ii) the appointment of Dr. Gayko to serve on the Nominating and Corporate Governance Committee.

View on SEC.gov

Summit Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193805-21-001525

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.